Tritanrix™-HepB
Phase 3Biologic
GSKTritanrix™-HepB is one of 41 biologic programs targeting Memory. It is currently in Phase 3.
1
Indications
8
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
169 competitors in Memory
#DrugCompanyPhaseTrials
1Lexapro
AbbViePhase 3
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
Vivarin
HHikma Pharmaceuticals LLC
Phase 3
Pneumococcal Vaccine
GSKPhase 3
Bupropion XL
GSKPhase 3
Epidiolex
Jazz PharmaceuticalsPhase 2
Cysteine Hydrochloride
NovartisPhase 2
Avandia
Alnylam PharmaceuticalsPhase 2
Rituxan
RochePhase 2
Activella
Eli LillyPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Immunogenicity2 trials
Memory1 trial
Vaccination1 trial
Rotavirus Vaccine1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tritanrix™-HepB. EMBL-EBI & Wellcome Sanger Institute.
- [4]